Phase I study of vinblastine and temsirolimus in pediatric patients with recurrent or refractory solid tumors: Canadian Cancer Trials Group Study IND.218-Reference-Cited by-同舟云学术

Phase I study of vinblastine and temsirolimus in pediatric patients with recurrent or refractory solid tumors: Canadian Cancer Trials Group Study IND.218

Published:2018-11-04 Issue:3 Volume:66 Page:e27540
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Deyell Rebecca J.¹^ORCID,Wu Bing²,Rassekh S. Rod¹,Tu Dongsheng³,Samson Yvan⁴,Fleming Adam⁵,Bouffet Eric²,Sun Xiaoqun³,Powers Jean³,Seymour Lesley³,Baruchel Sylvain²,Morgenstern Daniel A.²^ORCID

Affiliation:

1. Division of Pediatric Hematology/Oncology/BMT; University of British Columbia; British Columbia Children's Hospital and Research Institute; Vancouver British Columbia Canada

2. Department of Pediatrics; University of Toronto and New Agent and Innovative Therapy Program; The Hospital for Sick Children; Toronto Ontario Canada

3. Canadian Cancer Trials Group and Queen's University; Kingston Ontario Canada

4. Centre Hospitalier Universitaire Sainte-Justine; Montreal Quebec Canada

5. McMaster Children's Hospital at Hamilton Health Sciences; Hamilton Ontario Canada

Funder

Canadian Cancer Trials Group

Garron Family Cancer Centre

SickKids Foundation,

Great Cycle Challenge Canada

Canadian Cancer Society Research Institute

Publisher

Wiley

Subject